Kai Lin
Profile
Kai Lin worked as Senior Director & Head-Virology at Enanta Pharmaceuticals, Inc., Head-Biology at Idenix Pharmaceuticals LLC, Vice President-Virology at Atea Pharmaceuticals, Inc., and Head-Biology at Permeon Biologics, Inc. He holds a doctorate degree from the University of Pennsylvania and an undergraduate degree from Nankai University.
Former positions of Kai Lin
| Companies | Position | End |
|---|---|---|
| ATEA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/06/2022 |
Permeon Biologics, Inc.
 Permeon Biologics, Inc. BiotechnologyHealth Technology Permeon Biologics, Inc. develops intracellular biotherapeutics platform to enhance drug delivery. Its intraphilin technology platform leverages research on remodeling the surfaces of proteins to permit cell penetration without losing their structure or activity; and enables functional proteins to replace or restore defective pathways inside cells that cause disease. The company was founded by Douglas G. Cole, David R. Liu, John W. Ripple, and Noubar B. Afeyan in 2008 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
| IDENIX PHARMACEUTICALS INC | Corporate Officer/Principal | - |
| ENANTA PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Training of Kai Lin
| Nankai University | Undergraduate Degree |
| University of Pennsylvania | Doctorate Degree |
Experiences
Positions held
Linked companies
| Listed companies | 2 |
|---|---|
| ATEA PHARMACEUTICALS, INC. | Health Technology |
| ENANTA PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Idenix Pharmaceuticals LLC
 Idenix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA. | Health Technology |
Permeon Biologics, Inc.
Permeon Biologics, Inc. BiotechnologyHealth Technology Permeon Biologics, Inc. develops intracellular biotherapeutics platform to enhance drug delivery. Its intraphilin technology platform leverages research on remodeling the surfaces of proteins to permit cell penetration without losing their structure or activity; and enables functional proteins to replace or restore defective pathways inside cells that cause disease. The company was founded by Douglas G. Cole, David R. Liu, John W. Ripple, and Noubar B. Afeyan in 2008 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Kai Lin
